BUNNAGE MARK E. (EVP, Chief Scientific Officer) sold 13.5% of their position (2.02K shares) of VERTEX PHARMACEUTICALS INC / MA on the open market
Open‑market sale worth $930.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/12/2026ACC: 0000875320-26-000044
Officer· EVP, Chief Scientific Officer
Since Feb 2026
-3.15K
Net shares
Net seller
$1.46M
Total sold
1
Open market trades
0B · 1S
2
Total transactions
3.15K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−1.13K
Price / share
$468.41
Trade value
$527.90K
% of position
7.0%
2/10/2026
16.06K→14.94K
Common Stock
Direct
Shares
−2.02K
Price / share
$460.43
Trade value
$930.53K
% of position
13.5%
2/11/2026
14.94K→12.91K
Total
Net shares
−3.15K
Net value
-$1.46M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/10/2026 | F · Tax Withholding | −1.13K | $468.41 | $527.90K | 7.0% | 16.06K | 14.94K |
| Common Stock Direct | 2/11/2026 | S · Sale | −2.02K | $460.43 | $930.53K | 13.5% | 14.94K | 12.91K |
| Total | −3.15K | -$1.46M | ||||||
Derivative Transactions0
No derivative transactions reported